Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.
BACKGROUND:Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in huma...
Main Authors: | Stephen A Harrison, Andrea Dennis, Martine M Fiore, Matt D Kelly, Catherine J Kelly, Angelo H Paredes, Jennifer M Whitehead, Stefan Neubauer, Peter G Traber, Rajarshi Banerjee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6128474?pdf=render |
Similar Items
-
Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
by: Harrison, SA, et al.
Published: (2018) -
Therapy of experimental NASH and fibrosis with galectin inhibitors.
by: Peter G Traber, et al.
Published: (2013-01-01) -
Imaging biomarkers of NAFLD, NASH, and fibrosis
by: Veeral Ajmera, et al.
Published: (2021-08-01) -
Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
by: Sumit Kar, et al.
Published: (2019-01-01) -
Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
by: Weiguo Fan, et al.
Published: (2021-04-01)